Melior Discovery Enters New Pharmaceutical Collaboration
EXTON, Pa., August 06, 2007 /PRNewswire/ -- Melior Discovery, Inc. today announced that it has signed an agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) to apply Melior's theraTRACE(SM) indications discovery platform to identify possible new indications for multiple J&JPRD drug candidates. Financial terms were not disclosed.
Melior's theraTRACE platform is a comprehensive, multiplexed set of integrated in vivo models designed to systematically and rapidly identify previously unknown applications for pharmaceutical compounds. It can be applied to discovery, development stage and marketed agents and has already identified novel indications for a number of development stage drugs.
"This agreement presents a significant opportunity for Melior to deliver value through the application of our unique in vivo testing platform to a range of pre-clinical and development stage compounds," said Andrew Reaume, Ph.D., President and CEO of Melior. "Our theraTRACE indications discovery platform is already proving its value in our existing collaborations with Merck and Pfizer, as well as in screening for our own drug development efforts. We are delighted to be working with J&JPRD, and we look forward to a productive collaboration."
Melior's theraTRACE platform is designed to systematically test the potential efficacy of compounds across a large number of disease models rapidly and efficiently, using the same high quality in vivo models developed by leading pharmaceutical researchers to determine whether a drug candidate demonstrates sufficient efficacy to merit advancement into clinical development. Melior's proprietary multiplexed approach integrates multiple in vivo models and reduces the time, amount of test compound and number of test subjects needed, while also reducing the number of false positive results. As a result, Melior's platform provides major improvements in efficiency and effectiveness and a reduction in the overall cost of the new indications discovery effort.
About Melior Discovery
Melior Discovery is leading the transformation of pharmaceutical drug repositioning with its proprietary theraTRACE platform of multiple integrated in vivo models. Melior is using this unique capability to assist pharmaceutical and biotechnology partners in realizing the full value of their pipeline assets and to build an internal pipeline of development candidates. Dr. Christopher Lipinski, a well-known research pioneer who was recently named one of the top 10 most influential people in the pharmaceutical industry, works closely with Melior in the development of its technology and identification of drug candidates.
For more information, visit http://www.meliordiscovery.com or call Dr. Andrew Reaume, President and CEO of Melior.
Contacts:
Melior Discovery Media:
Andrew Reaume GendeLLindheim BioCom Partners
President & CEO Barbara Lindheim
(610) 280-0633 (212) 918-4650
areaume@meliordiscovery.com
CONTACT: Andrew Reaume, President and CEO, of Melior Discovery, Inc.,+1-610-280-0633, ; or Barbara Lindheim ofGendeLLindheim BioCom Partners for Melior Discovery, Inc., +1-212-918-4650 areaume@meliordiscovery.com
Web site: http://www.meliordiscovery.com/
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights
reserved.
A United Business Media Company
Pharma Industry News Archive
2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec
